FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208712775> ?p ?o ?g. }

• W3208712775 endingPage "S138" @default.
• W3208712775 startingPage "S138" @default.
• W3208712775 abstract "Purpose/Objective(s)Mismatch repair deficiency (dMMR) is found in approximately 25% of endometrial cancers (EC), yet it remains unknown how this information should be incorporated into adjuvant treatment paradigms. Ongoing trials are investigating the potential use of immunotherapy in conjunction with radiotherapy for the adjuvant treatment of dMMR patients with high-intermediate risk (HIR) features. We hypothesized that dMMR status is associated with higher rates of recurrence in both low-intermediate risk (LIR) and HIR subgroups. We examined the impact of dMMR status on prognosis among patients with early-stage endometrioid EC treated with vaginal brachytherapy (VB).Materials/MethodsWe performed a retrospective review of 198 patients who were treated with adjuvant VB for FIGO stage I or II endometrioid EC and had known MMR status. Both LIR and HIR patients (per GOG 249 criteria) were included. Patients with non-endometrioid and mixed histologies and patients treated with pelvic radiotherapy were excluded. Patient, tumor, and treatment characteristics were compared between patients with proficient mismatch repair (pMMR) and dMMR using c2 tests for categorical variables and t-tests for continuous variables. Recurrence free survival (RFS) and overall survival (OS) were analyzed with Kaplan-Meier estimates, the log-rank test, and Cox proportional hazards regression.ResultsPatients with dMMR compared to pMMR were more likely to have grade 2-3 tumors (75% vs. 57%, P = 0.012), lympho-vascular invasion (40% vs. 25%, P = 0.023), and HIR classification (65% vs. 49%, P = 0.038). There were no other differences in clinicopathologic or treatment characteristics. Median follow-up time for dMMR and pMMR patients was 37.5 and 37 months, respectively. Three-year RFS was inferior for dMMR compared to pMMR patients (75% vs. 96%, P = 0.001). dMMR patients compared to pMMR had similarly reduced 3-year RFS both within the LIR (74% vs. 100%, P = 0.026) and HIR (75% vs. 91%, P = 0.038) subgroups. Three-year OS was excellent across all categories and was not different between dMMR/pMMR patients (98% vs. 97%, P = 0.653) or HIR/LIR patients (97% vs. 97%, P = 0.999). On multivariable Cox regression, dMMR status was the only significant prognostic variable for RFS (HR 3.774, CI 1.495-9.526, P = 0.005), though it was not significant for OS. While failures were more likely in the dMMR cohort, salvage rates were high, and treatment included surgery (29.4%), pelvic RT (41.2%), chemotherapy (70.6%), and immunotherapy (47.1%).ConclusionFollowing VB, patients with dMMR have poorer RFS compared to pMMR patients regardless of HIR/LIR risk classification. Increased monitoring for early salvage intervention and/or expansion of eligibility to clinical trials incorporating immune checkpoint inhibitors should be considered for both HIR and LIR patients with dMMR. Mismatch repair deficiency (dMMR) is found in approximately 25% of endometrial cancers (EC), yet it remains unknown how this information should be incorporated into adjuvant treatment paradigms. Ongoing trials are investigating the potential use of immunotherapy in conjunction with radiotherapy for the adjuvant treatment of dMMR patients with high-intermediate risk (HIR) features. We hypothesized that dMMR status is associated with higher rates of recurrence in both low-intermediate risk (LIR) and HIR subgroups. We examined the impact of dMMR status on prognosis among patients with early-stage endometrioid EC treated with vaginal brachytherapy (VB). We performed a retrospective review of 198 patients who were treated with adjuvant VB for FIGO stage I or II endometrioid EC and had known MMR status. Both LIR and HIR patients (per GOG 249 criteria) were included. Patients with non-endometrioid and mixed histologies and patients treated with pelvic radiotherapy were excluded. Patient, tumor, and treatment characteristics were compared between patients with proficient mismatch repair (pMMR) and dMMR using c2 tests for categorical variables and t-tests for continuous variables. Recurrence free survival (RFS) and overall survival (OS) were analyzed with Kaplan-Meier estimates, the log-rank test, and Cox proportional hazards regression. Patients with dMMR compared to pMMR were more likely to have grade 2-3 tumors (75% vs. 57%, P = 0.012), lympho-vascular invasion (40% vs. 25%, P = 0.023), and HIR classification (65% vs. 49%, P = 0.038). There were no other differences in clinicopathologic or treatment characteristics. Median follow-up time for dMMR and pMMR patients was 37.5 and 37 months, respectively. Three-year RFS was inferior for dMMR compared to pMMR patients (75% vs. 96%, P = 0.001). dMMR patients compared to pMMR had similarly reduced 3-year RFS both within the LIR (74% vs. 100%, P = 0.026) and HIR (75% vs. 91%, P = 0.038) subgroups. Three-year OS was excellent across all categories and was not different between dMMR/pMMR patients (98% vs. 97%, P = 0.653) or HIR/LIR patients (97% vs. 97%, P = 0.999). On multivariable Cox regression, dMMR status was the only significant prognostic variable for RFS (HR 3.774, CI 1.495-9.526, P = 0.005), though it was not significant for OS. While failures were more likely in the dMMR cohort, salvage rates were high, and treatment included surgery (29.4%), pelvic RT (41.2%), chemotherapy (70.6%), and immunotherapy (47.1%). Following VB, patients with dMMR have poorer RFS compared to pMMR patients regardless of HIR/LIR risk classification. Increased monitoring for early salvage intervention and/or expansion of eligibility to clinical trials incorporating immune checkpoint inhibitors should be considered for both HIR and LIR patients with dMMR." @default.
• W3208712775 created "2021-11-08" @default.
• W3208712775 creator A5010339370 @default.
• W3208712775 creator A5018653616 @default.
• W3208712775 creator A5021257078 @default.
• W3208712775 creator A5043197892 @default.
• W3208712775 creator A5062471254 @default.
• W3208712775 creator A5071115299 @default.
• W3208712775 creator A5086674396 @default.
• W3208712775 date "2021-11-01" @default.
• W3208712775 modified "2023-10-16" @default.
• W3208712775 title "Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal Brachytherapy" @default.
• W3208712775 doi "https://doi.org/10.1016/j.ijrobp.2021.07.311" @default.
• W3208712775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700475" @default.
• W3208712775 hasPublicationYear "2021" @default.
• W3208712775 type Work @default.
• W3208712775 sameAs 3208712775 @default.
• W3208712775 citedByCount "0" @default.
• W3208712775 crossrefType "journal-article" @default.
• W3208712775 hasAuthorship W3208712775A5010339370 @default.
• W3208712775 hasAuthorship W3208712775A5018653616 @default.
• W3208712775 hasAuthorship W3208712775A5021257078 @default.
• W3208712775 hasAuthorship W3208712775A5043197892 @default.
• W3208712775 hasAuthorship W3208712775A5062471254 @default.
• W3208712775 hasAuthorship W3208712775A5071115299 @default.
• W3208712775 hasAuthorship W3208712775A5086674396 @default.
• W3208712775 hasBestOaLocation W32087127751 @default.
• W3208712775 hasConcept C121608353 @default.
• W3208712775 hasConcept C126322002 @default.
• W3208712775 hasConcept C143998085 @default.
• W3208712775 hasConcept C146357865 @default.
• W3208712775 hasConcept C151730666 @default.
• W3208712775 hasConcept C2777088508 @default.
• W3208712775 hasConcept C2777416452 @default.
• W3208712775 hasConcept C2777863537 @default.
• W3208712775 hasConcept C50382708 @default.
• W3208712775 hasConcept C509974204 @default.
• W3208712775 hasConcept C71924100 @default.
• W3208712775 hasConcept C86803240 @default.
• W3208712775 hasConceptScore W3208712775C121608353 @default.
• W3208712775 hasConceptScore W3208712775C126322002 @default.
• W3208712775 hasConceptScore W3208712775C143998085 @default.
• W3208712775 hasConceptScore W3208712775C146357865 @default.
• W3208712775 hasConceptScore W3208712775C151730666 @default.
• W3208712775 hasConceptScore W3208712775C2777088508 @default.
• W3208712775 hasConceptScore W3208712775C2777416452 @default.
• W3208712775 hasConceptScore W3208712775C2777863537 @default.
• W3208712775 hasConceptScore W3208712775C50382708 @default.
• W3208712775 hasConceptScore W3208712775C509974204 @default.
• W3208712775 hasConceptScore W3208712775C71924100 @default.
• W3208712775 hasConceptScore W3208712775C86803240 @default.
• W3208712775 hasIssue "3" @default.
• W3208712775 hasLocation W32087127751 @default.
• W3208712775 hasLocation W32087127752 @default.
• W3208712775 hasOpenAccess W3208712775 @default.
• W3208712775 hasPrimaryLocation W32087127751 @default.
• W3208712775 hasRelatedWork W1977834245 @default.
• W3208712775 hasRelatedWork W2053104579 @default.
• W3208712775 hasRelatedWork W2053331699 @default.
• W3208712775 hasRelatedWork W2084674146 @default.
• W3208712775 hasRelatedWork W2383944262 @default.
• W3208712775 hasRelatedWork W2921111554 @default.
• W3208712775 hasRelatedWork W2951028713 @default.
• W3208712775 hasRelatedWork W3092193115 @default.
• W3208712775 hasRelatedWork W4205904040 @default.
• W3208712775 hasRelatedWork W4246030040 @default.
• W3208712775 hasVolume "111" @default.
• W3208712775 isParatext "false" @default.
• W3208712775 isRetracted "false" @default.
• W3208712775 magId "3208712775" @default.
• W3208712775 workType "article" @default.